The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...